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a b s t r a c t
Background: The relationship between tobacco and depressive symptoms has been examined. However,
there is little information on the evolution of these symptoms when an individual quits. The aim of this
study was to analyze the evolution of depressive symptoms over time (pre-, post-treatment, 1-, 3-, 6-,
and 12-months follow-up) in relation to smoking status 12 months after having received a psychological
treatment for smoking cessation.
Method: The sample was made up of 242 adults who received cognitive-behavioral treatment for
smoking cessation (64.4% women; mean age¼41.71 years). The BDI-II was used to assess depressive
symptomatology. Participants were classified into three groups according to smoking status at 12-
months follow-up (abstainers, relapsers, and smokers).
Results: There were no significant differences in depressive symptoms among the three groups at pre-
treatment. At the end of treatment, abstainers and relapsers presented less depressive symptomatology
than smokers. At follow-up, abstainers continued to present less depressive symptomatology than
smokers, whereas in relapsers, symptoms began to increase as the relapses occurred. Regarding the
evolution of depressive symptomatology, the abstainer and relapser groups showed a significant re-
duction at the end of treatment. Only in the group of abstainers did the decrease continue during 12
months follow-up.
Limitations: The decrease of the initial sample size from 562 to 242 participants. Variables such as self-
esteem and self-efficacy were not assessed.
Conclusions: Smoking cessation is associated with a decrease in depressive symptomatology, that is
maintained over time. In contrast, relapse is associated with an increase of such symptoms. These
findings signify the potential importance of addressing depressive symptomatology in smoking cessation
treatment.
& 2015 Published by Elsevier B.V.
1. Introduction
The relationship between tobacco consumption and depression
is well established (Tsoh et al., 2000) and has been addressed from
multiple perspectives in recent years. People with depression are
more likely to be smokers (Breslau et al., 1998; Holma et al., 2013;
Lasser et al., 2000) and to be nicotine dependent (Dierker and
Donny, 2008). The evidence also indicates that smokers have a
higher risk of experiencing depression (Bandiera et al., 2015;
Breslau and Johnson, 2000; Grant et al., 2004).
With regard to nicotine withdrawal symptoms, which include
some depressive-like symptoms (Hughes, 2007b), findings in-
dicate that smokers with a history of depression are more likely to
experience depressive symptoms, and of greater severity, in the
withdrawal syndrome (Covey et al., 1990; Langdon et al., 2013). In
addition, smokers frequently use tobacco to cope with discomfort
that these symptoms cause (Leventhal et al., 2013).
People with depression also have more difficulty quitting
smoking (Ziedonis et al., 2008) and are more likely to relapse
(Brodbeck et al., 2014; Zvolensky et al., 2015). In their meta-ana-
lysis, Hitsman et al. (2013) found that the existence of a history of
major depression in the past, but not in the present, hinders the
achievement of abstinence. In addition, evidence suggests that
specific symptoms of depression such as anhedonia and low po-
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Leventhal et al. (2014) found that life-time anhedonia predicted
smoking cessation outcome better than history of depressive dis-
order and lifetime depressed mood. Further, studies have found
that the introduction of cognitive-behavioral mood management
techniques significantly improves the effectiveness of smoking
cessation interventions (Gierisch et al., 2012). For example, Mac-
Pherson et al. (2010), examined the effect of including behavioral
activation techniques in a smoking cessation intervention, and
found improved abstinence outcomes and decreases in depressive
symptomatology.
The findings regarding whether smoking cessation increases
the likelihood of depression are inconclusive. Tsoh et al. (2000)
found that the likelihood of experiencing depression is similar
between those who quit smoking and those who do not, except for
those smokers with a previous history of depression, whose risk
would be maintained for at least 6 months, according to Glassman
et al. (2001). The review by Ragg et al. (2013) indicates that the
risk of experiencing depressive symptoms when quitting is not
higher in individuals with a history of major depression, because
their mood may improve after quitting smoking. Similarly, in a
study of smokers with depression, Mathew et al. (2013) found that
both those who quit and those who remained abstinent demon-
strated significant improvements in psychological functioning
compared to those who continued smoking at 3 and 6 months
follow-up. The authors note that the increase in depressive
symptoms seems to be more closely related to the failure to suc-
cessfully quit smoking.
In an attempt to explain these discrepancies, Hughes (2007a)
notes that the belief that smoking cessation increases depressive
symptomatology is due to the attribution that nicotine has anti-
depressant effects and to the symptomatology associated with the
withdrawal syndrome that appears after quitting. However, some
research suggests that smokers do not smoke in order to gain the
antidepressant effects of smoking and furthermore, depressive
symptoms are not the most frequent symptoms when undergoing
withdrawal. In fact, with respect to other drugs, the evidence in-
dicates that smoking cessation is related to an improvement of
depressive symptoms. Similarly, a recent meta-analysis of long-
itudinal studies carried out by Taylor et al. (2014) found that both
in general and clinical populations (individuals who suffer some
mental disorder), smoking cessation is associated with a decrease
in depression, anxiety, and stress and an improvement in positive
mood and quality of life.
Therefore, the published studies confirm the existence of a
clear relationship between smoking and depression, although
there are discrepancies between some of the studies about the
nature of this relationship and how the variables affect each other.
Evaluation of depressive problems at different moments of the
process of smoking cessation would help to clarify this relation-
ship, especially taking into account not only the comparison of
smokers and abstainers but also including those who initially quit
smoking but who relapse later on.
The aim of the present study is to analyze the relationship
between depressive symptomatology, assessed with the Beck De-
pression Inventory-II (BDI-II) at different times (pre-, post-treat-
ment and at 1-, 3-, 6- and 12-months follow-up) and smoking
status 12 months after having received a cognitive-behavioral
treatment for smoking cessation. To our knowledge, this is the first
study that compares depressive symptoms at different times
across three groups depending on smoking status at 12 months
follow-up: abstainers (those who quit smoking since the end of
treatment until 12-months follow-up), smokers (those who never
quit smoking), and relapsers (those who quit smoking at the end
of treatment but who relapsed before the 12-months follow-up).
The hypotheses of this study are: (1) people who quit smoking at
the end of treatment and remain abstinent at 12 months have
fewer depressive symptoms at all the assessed times (pre-, post-
treatment and follow-ups) compared to participants who did not
quit smoking and those who relapsed, and (2) as the time without
smoking increases, people who remain abstinent at 12 months
present a greater decrease of depressive symptoms than smokers
and relapsers at all the evaluations performed.
2. Methods
2.1. Participants
The initial sample consisted of 562 smokers who received
cognitive-behavioral treatment for smoking cessation who met the
inclusion and exclusion criteria of the study. Inclusion criteria
were: aged 18 or over; wishing to participate in the treatment
program; and smoking 10 or more cigarettes per day. Exclusion
criteria were: a diagnosis of severe mental disorder (bipolar dis-
order and/or psychotic disorder); concurrent dependence on other
substances (alcohol, cannabis, cocaine and/or heroin); having
participated in the same or similar treatment over the previous
year; having received pharmacological smoking cessation treat-
ment (nicotine replacement therapy, bupropion, varenicline) in
the past year; suffering from a physical pathology with a high life
risk that would require immediate individual intervention (e.g.,
recent myocardial infarction); smoking a type of tobacco other
than cigarettes (e.g., cigars); and failing to attend the first treat-
ment session. All participants were recruited between 2009 and
2014.
As the aim of this study was to assess depressive symptoma-
tology across all follow-ups, we included only those cases who
completed the BDI-II at all times (pre-, post-, and 1-, 3-, 6-, and 12-
months follow-up). Therefore, the final sample was made up of
242 smokers.
2.2. Instruments
2.2.1. Smoking Habit Questionnaire
The smokers filled out the 56-item Smoking Habit Ques-
tionnaire (Becoña, 1994), designed to gather information both on
sociodemographic variables (gender, age, marital status, educa-
tional level) and tobacco use (i.e., number of cigarettes smoked per
day).
2.2.2. Fagerström Test for Nicotine Dependence
(FTND, Heatherton et al., 1991). This scale is made up of 6 items
and the scores range from 0 to 10 points. Information related to
nicotine dependence was obtained at baseline. In the present
sample, the reliability obtained by means of Cronbach's alpha was
0.59.
2.2.3. Beck Depression Inventory-II
(BDI-II; Beck et al., 1996; Sanz and Vázquez, 2011). This is a 21-
item self-report scale measuring current depressive symptoms.
The internal consistency obtained in Spanish sample by Cronba-
ch's alpha was 0.90.
2.2.4. Microþ Smokerlyzer
(Bedfont Scientific Ltd., Sittingbourne, UK). This was used to
measure carbon monoxide (CO) in exhaled air in order to corro-
borate self-reported abstinence at the end of treatment and at
follow-ups (1, 3, 6 and 12 months).
2.3. Procedure
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to-face interview and the above-described instruments were ad-
ministered. All the smokers gave their informed consent for par-
ticipation, and the study was authorized by the Bioethics Com-
mittee of the University of Santiago de Compostela. Next, the
Smoking Cessation Program (Becoña, 2007), a cognitive-behavioral
treatment, was administered in groups of 6–8 participants. This is
a standardized and manualized treatment consisting of six ses-
sions (one per week) with the following elements: treatment
contract, self-report and graphic representation of cigarette con-
sumption, information about tobacco, stimulus control, activities
for the avoidance of withdrawal syndrome, physiological feedback
(CO in exhaled air) on cigarette consumption, nicotine fading
(change of cigarette brands each week progressively decreasing
the intake of nicotine and tar), and relapse-prevention strategies.
There was a face-to-face follow-up 1, 3, 6, and 12 months after
treatment. Self-reported abstinence at the end of treatment and at
each follow up was assessed by CO in exhaled air (COo10 ppm).
Biochemically validated smoking status was used rather than self-
reported smoking status. Participants did not use pharmacological
smoking cessation treatment during the Smoking Cessation Pro-
gram or during follow-up.
The criteria used for point-prevalence abstinence at the end of
treatment was not smoking in the past 24 h; at 1 and 3 months
follow-up point prevalence abstinence was defined as not smoking
in the past 7 days and at 6 and 12 months follow-up not smoking
in the past 30 days. A participant presenting continuous ab-
stinence at the 12-months follow-up (not having smoked, not even
a puff since the end of treatment) was considered to belong to the
abstainer group. Those who did not quit smoking at the end of
treatment and continued smoking during the follow-ups were
considered smokers, and those who stopped smoking at the end of
the treatment but were smoking during follow-up were con-
sidered relapsers (West et al., 2005).
2.4. Statistical analysis
To examine possible differences as a function of smoking status
at 12 months (smokers, relapsers, and abstainers) in demographic
and tobacco consumption variables and pretreatment depressive
symptomatology, we used chi-square and Snedecor's F. To de-
termine the effect size, we used Cramer's V and eta-square,
respectively.
Mean scores in depressive symptoms were compared among
the three groups (smokers, relapsers, and abstainers) at all times
(pre- and posttreatment and of 1-, 3-, 6- and 12-months follow-
ups) and a one factor ANOVA was carried out. For post hoc com-
parisons, we used the Bonferroni method. To correct the absence
of homoscedasticity, we applied a correction of F (Brown–Forsythe
F – Brown and Forsythe, 1974). For post hoc analysis of the Brown–
Forsythe F, we used Games–Howell's method (Games and Howell,
1976).
To assess longitudinal changes in depressive symptoms within
subjects in each of the three groups, we used a repeated measures
ANOVA. The repeated measures factor was the BDI-II score at pre-
and posttreatment and at 1-, 3-, 6- and 12-months follow-up. We
used the Greenhouse–Geisser F (FGG) to correct for the absence of
sphericity, in order to accommodate more general covariance
structures for the repeated measures (Greenhouse and Geisser,
1959). Post hoc analyses were performed with the Bonferroni test.
Analyses were performed with the SPSS 20, and the statistical
significance level was set at r0.05.
3. Results
The average age of participants was 41.71 years (SD¼10.11);
37.6% of the sample were male and 62.4% female. The average
number of cigarettes smoked per day was 20.57 (SD¼7.11); 41.7%
had higher education and more than one half (55%) were married
or living as a couple. The mean nicotine dependence score (ac-
cording to the Fagerström Test for Nicotine Dependence - FTND)
was 5.13 (SD¼2.08).
At the end of treatment, 79.8% of the participants (N¼242) had
quit smoking. For this study, we divided the sample into three
groups, as a function of the participants' smoking status at 12
months: smokers (n¼49), abstainers (n¼91), and relapsers
(n¼102). Fifty-two percent (n¼53) of participants in the relapser
group had relapsed before the 3-month follow-up.
We found no significant differences as a function of socio-
demographic characteristics (age, gender, marital status, and level
of education) or in pretreatment BDI-II scores among the three






































































































































Demographics, smoking history, and depression variables at pretreatment among smoking status groups at 12 months (N¼242).
Smokers (n¼49) Relapsers (n¼102) Abstainers (n¼91) χ2 p Cramer's V
n % n % N %
Gender 0.295 0.863 0.035
Female 29 59.2 65 63.7 57 62.6
Male 20 40.8 37 36.3 34 37.4
Marital Status 3.020 0.806 0.079
Single 15 30.6 39 38.3 28 30.8
Married 29 59.2 50 49 54 59.3
Divorced 4 8.2 10 9.8 8 8.8
Widowed 1 2 3 2.9 1 1.1
Educational Level 5.996 0.199 0.111
Basic 12 24.5 22 21.6 22 24.2
Middle 23 46.9 36 35.3 26 28.6
Higher 14 28.6 44 43.1 43 47.2
FTND 7.115a 0.029 0.171
Total scoreo6 21 42.9 56 54.9 60 65.9
Total scoreZ6 28 57.1 46 45.1 31 34.1
M SD M SD M SD F p η2
Age 43.86 8.85 42.04 11.44 40.20 8.95 2.366 0.114 0.018
CPD 23 7.90 20.73 6.69 19.08 6.80 4.732a 0.010 0.041
BDI-II pre-treat. 13.12 11.31 9.45 10.20 9.33 10.27 2.488 0.085 0.020
Note. FTND: Fagerström Test for Nicotine Dependence; CPD: Cigarettes Per Day; BDI-II: Beck Depression Inventory II.
a Significant intergroup differences between Abstainers and Smokers.
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abstainers and smokers in the FTND (χ2¼7.115, po .05) and the
number of cigarettes/day pretreatment (F¼4.732, po0.01) (see
Table 1).
3.1. Smoking status at the 12-months follow-up and depression
across time (pre- and posttreatment and follow-ups)
As shown in Table 2, abstainers had a lower BDI-II score at the
end of treatment and at all follow-ups than smokers. Abstainers
also presented fewer depressive symptoms than relapsers, but
only at the 3-, 6-, and 12-months follow-ups. Additionally, we also
found that the relapser group scored significantly lower in the
BDI-II than the smokers at the end of treatment and at 6-month
follow-up.
3.2. Evolution of depression from pretreatment to 12-months follow-
up
Regarding the evolution of depressive symptomatology, the
repeated measures analysis yielded differences in depressive
symptoms over time as a function of smoking status at 12 months
[FGG (8.68, 1032.80)¼3.205, p¼0.001, η2¼0.026], adjusting for
nicotine dependence (FGG, p4 .05). Therefore, the means pre-
sented within the group are estimated means after including these
covariates (see Fig. 1).
Post-hoc comparisons show that the abstainers' group was the
only one that presented significant differences at the end of
treatment and at all follow-ups in comparison to pretreatment
assessment. As time went by without smoking, their depressive
symptomatology decreased, and the most important reduction
occurred at the 3-month follow-up (5.04 marginal points)
compared to the pretreatment assessment.
The group of relapsers only presented significant differences
between the pre- and post-treatment assessments. As soon as they
quit smoking, the depressive symptoms decreased, but these dif-
ferences disappeared when relapses occurred. In the group of
smokers there were no significant differences in depressive
symptomatology either at the initial level, at the end of treatment,
or at follow-up.
4. Discussion
The present study aimed to analyze the relationship between
the evolution of depressive symptoms and smoking status at 12
months follow-up in smokers who received a cognitive-behavioral
treatment for smoking cessation. The presence of depressive
symptoms as measured with the BDI-II was assessed at different
times (pre-, post-treatment, and at 1-, 3-, 6-, and 12-months fol-
low-ups).
Differences in terms of sociodemographic characteristics (age,
gender, marital status and level of education) among the three
groups were not found. Berlin et al. (2010) did not find differences
between abstinent and smokers in age, gender and depression at
baseline characteristics either. In reference to depressive symp-
toms scores, we have not reached differences in the BDI-II scores
at baseline. In this sense, Kahler et al. (2002) showed that smokers
who were abstinent had lower BDI-II scores at baseline than
smokers however, they also concluded that giving up smoking
provokes a decrease in depressive symptoms.
The first hypothesis, that people who quit smoking and remain
abstinent at 12 months have fewer depressive symptoms at all
assessment times was partially supported.
The results showed that the group of abstainers had fewer
depressive symptoms than the other two groups at all times
analyzed, except for the pretreatment assessment, where we
found no significant differences. That is, the depressive symptoms
they presented when initiating the smoking cessation treatment
did not determine treatment success either at the short or the long
term. Previous studies suggesting that people with depression
have more difficulty quitting and a higher likelihood of relapse
(i.e., Ziedonis et al., 2008; Zvolensky et al., 2015). Also, Leventhal
et al. (2014) showed that lifetime depressive symptoms are asso-
ciated with continuing to smoke. There may be other variables
such as the existence of a history of depression in the past, as
indicated by Hitsman et al. (2013), which determine treatment
outcome, so that the presence of this type of symptoms should not
be an obstacle for people to start a smoking cessation treatment
and to succeed in it.
In the remaining evaluations (post-treatment and follow-ups),
people who quit smoking and remained abstinent at 12 months






































































































































Mean scores on the Beck Depression Inventory according to time (treatment and follow-ups) and smoking status at 12-months follow-up.
Smokers (n¼49) Relapsers (n¼102) Abstainers (n¼91) F p η2
M SD M SD M SD
Time
Pre-treatment 13.12 11.31 9.45 10.20 9.33 10.27 2.488 .085 .020
Post-treatment 11.90 12.32 6.76 6.24 6.31 7.65 6.263 .003 .064
Follow-ups
1 month 11.02 10.79 7.12 8.96 5.84 6.76 5.203 .007 .047
3 months 12.04 12.37 7.77 8.73 4.41 5.68 10.118 .001 .095
6 months 12.84 11.90 7.99 9.40 4.62 7.15 11.060 .001 .096
12 months 10.78 11.70 8.80 10.03 4.54 6.31 7.774 .001 .069
Fig. 1. Estimated means in depression (BDI-II) according to time and smoking
status at 12 months, adjusting for nicotine dependence (N¼242).
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compared with people who did not quit smoking. In a sample of
patients with chronic depressive disorder, Mathew et al. (2013)
found that smokers who achieved prolonged abstinence showed
decreased levels of affective symptoms at 6 months follow up.
Therefore, quitting smoking may be associated with improve-
ments in mood (Taylor et al., 2014) or at the very least does not
result in an increase in depressive symptoms Capron et al. (2014).
Conversely, previous studies show that depressive symptoms in-
crease after quitting smoking due to the loss of the antidepressant
effects of nicotine or to nicotine withdrawal (Hughes, 2007b).
Another outcome that supports the importance of smoking ces-
sation for mood improvement is that the relapser group increased
their scores in depression in comparison with the group of ab-
stainers as of the 3-month follow-up (up to that time, the scores
were similar). This period has been shown as the most likely for
smoking relapse (Piñeiro et al., 2014). Berlin et al. (2010) showed
that smokers who relapse exhibited an increase in depression and
anxiety symptoms, as well as suicidal ideation. As pointed out by
Zvolensky et al. (2015), further investigations must examine
whether the increase in depressive symptoms leads to relapse or
whether, on the contrary, after a relapse there is an increase in
depressive symptoms due to, for example, reduction of self-
efficacy.
The results of this study support the second hypothesis. In the
group that remained abstinent at 12 months follow-up, there was
a gradual decrease of depressive symptomatology from pretreat-
ment until the 12 months follow-up. In the groups of smokers and
relapsers, only at the end of treatment was there an improvement
of symptoms. This decrease produced during treatment in all the
groups might be due to the fact that the treatment includes psy-
chological strategies that may also be useful for mood manage-
ment (e.g., problem solving, stress management), but after com-
pleting the treatment or if there is a relapse, these positive effects
on mood disappear.
Ischaki and Gratziou (2009) and Brodbeck et al. (2014) point to
self-efficacy and self-esteem as mediating variables between de-
pression and smoking cessation. Compared with relapsers or with
those who never stopped smoking, those who remain abstinent—
despite not differing in depression scores at the beginning of
treatment—probably use the strategies to maintain abstinence that
they learned throughout the treatment, thereby increasing their
self-efficacy and the likelihood of not relapsing (Marlatt and Do-
novan, 2005).
This study allows us to conclude that people who quit smoking
by means of a cognitive behavioral treatment present a decrease in
depressive symptomatology that is maintained if they do not re-
lapse. The mood management strategies that are used in the
treatment may be decisive, not only to increase the probability of
smoking cessation but also to improve mood; hence, the im-
portance of including them in treatments regardless of whether or
not depression is present (Brown et al., 2001; Haas et al., 2004;
MacPherson et al., 2010). Even though in the current study, the
mean depression scores within the group of abstainers are within
the normal range at pretreatment and 12 months follow up, pre-
vious studies includingQ2 Lenventhal et al. (2014) and Niaura et al.
(2001) have shown that lower level depressive symptoms can
predict treatment outcomes. For this reason our results have a
clinical significance for smoking treatment. Therefore, we can also
conclude that smoking cessation is recommended even in those
people who were previously thought to have difficulties due to
presenting depressive problems.
4.1. Limitations and future directions
Among the limitations of the present study, we highlight the
decrease of the initial sample size from 562 to 242 participants, as
we could only use those smokers of whom we had BDI-II data at
all the assessment times. However, we point out that this is the
first study to perform an assessment of depressive symptoms at
different key periods of the cessation process and during the
period of greatest risk of relapse. A second limitation is that
variables such as self-esteem and self-efficacy were not assessed
within the current study. These variables could be relevant in
explaining the relationship between depression and smoking
cessation. However, as noted above, this opens new lines of re-
search to continue working.
Among the strengths of this study, we note that, in addition to
performing an assessment of the evolution of depressive symp-
toms, we took into account not only the group of abstainers and
the group of smokers but also a group of the people who relapsed
after quitting. In addition, we used the most restrictive abstinence
criterion, continuous abstinence, which allows more accurate in-
terpretation of the results obtained (West et al., 2005).
As stated by Berlin et al. (2009), the relationship between
smoking cessation and depression is complex. Further studies
conducted with people with past or current symptoms of de-
pression are needed as there are few studies within this area
(Weinberger et al., 2013). This study provides useful information
on what occurs after treatment and at follow-up regarding the
evolution of depressive symptoms and the benefits that smoking
cessation may have on mood.
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